Results from the first Phase III trial in obesity and overweight investigating the GIPR/GLP-1R co-agonist tirzepatide, which is currently approved for the treatment of type 2 diabetes and has resulted in marked body-weight reductions in type 2 diabetes [5, 43,44,45,46], were published in 2022 [28]
As peptides are involved in an immense number of physiological processes, it was logical to further exploit them for cosmetic applications
Using a properly dosed, well-formulated GHK-Cu product consistently is what allows the cumulative effect to occur.
With research examining how TB-500 influences corneal epithelial cell migration and re-epithelialisation following corneal injury, corneal angiogenesis, and ocular surface biology
It directly suppresses pro-inflammatory cytokines, including IL-6 and TNF-, without compromising immune defense
HEALTH SUPPLEMENT NOT FOR MEDICINAL USE